NEWS

We are delighted to announce that Haier Biomedical has been officially approved as a supplier on the NHS Supply Chain Pathology Framework, which will run from 2024 to 2028. This achievement marks a significant milestone for our company and underscores our commitment to delivering high-quality laboratory equipment and services to the healthcare sector.

The Haier Biomedical Blood Banking Centrifuge LX-75L2400R has become the preferred choice in blood bank research due to its superior safety features, large storage capacity, exceptional separation efficiency, and intelligent operation. As a leading product in the industry, the LX-75L2400R addresses user needs and challenges comprehensively. By overcoming the limitations of traditional equipment, it delivers groundbreaking performance with the capability of processing "16 bags of slurry in one operation" and a lifespan of 15 years. These core technological innovations highlight its unique advantages in efficiency and reliability, offering robust support for user experiments.

Haier Biomedical, warmly welcomed the esteemed visit of the Togolese Ambassador to China and Presidential Advisor. The visit not only serves to deepen the Togolese government's understanding of Haier Group and Haier Biomedical, but also enhanced a significant step towards the advancement and cooperation in public health initiatives. The exchange of knowledge and experiences during this visit is poised to pave the way for enhanced cooperation that will benefit both nations' healthcare sectors. 

The INTERPHEX Week Tokyo, held from June 26 to 28, 2024, drew international interest from the medical and pharmaceutical domains. As a leading-edge comprehensive platform in Asia for the pharmaceutical and cosmetics sectors, INTERPHEX Week Tokyo boasts a history spanning over two decades. Comprising four distinct exhibitions focusing on pharmaceuticals, life sciences, medical devices, and beyond, this event unites experts across diverse industries and ranks among Japan's premier professional expos.

As a leading global brand in the digital life sciences and medical innovation landscape, Haier Biomedical continues to make remarkable advancements on the world stage with its exceptional products and cutting-edge technological solutions. Its recent successful implementations across diverse sectors in Malaysia underscore its outstanding performance and impact in the international market.

Haier Biomedical, a leading provider of innovative laboratory solutions, has strategically collaborated with DKSH Singapore, a renowned industry leader in the region. Together, they are spearheading the delivery of comprehensive equipment and technical solutions for life science laboratories in Singapore.

Recently, a deadly bacterium known as "flesh-eating bacteria" has been spreading in Japan, drawing global attention. The illness caused by this bacterium, medically referred to as Streptococcal Toxic Shock Syndrome (STSS), is caused by β-hemolytic streptococcal exotoxins and has an extremely high fatality rate of around 30%.

Hemolytic streptococcus (Group A Streptococcus, GAS) is a Gram-positive bacterium that can cause a variety of serious infections, including pharyngitis, necrotizing fasciitis, and sepsis.

Recently, the World Health Organization (WHO) released its 2023 contract awards to Chinese suppliers for goods and services. Haier Biomedical topped the list in terms of total contract value among all Chinese suppliers, according to third-party data.

On June 27th, the 39th International Society of Blood Transfusion (ISBT) International Congress will be successfully concluded. As a global influential event in this field, this congress attracted transfusion medical professionals from over 100 countries. Haier Biomedical, a global leading provider of digital solutions for life sciences and medical innovation, showcased its latest technologies and solutions in intelligent blood management to the world, further enhancing its brand influence in the global market.